Jupiter Life Line Hospitals Limited (JLHL)

Jupiter Life Line Hospitals Limited has informed the exchanges that company officials will participate in an in-person Investor Conference organized by PL Capital. The meeting is scheduled for September 28, 2026, between 1:00 pm and 5:00 pm. The company confirmed that only publicly available information will be discussed and no unpublished price sensitive information (UPSI) will be shared.

• Investor conference scheduled for September 28, 2026
• Meeting duration from 1:00 pm to 5:00 pm
• Organized by PL Capital via in-person mode
• No unpublished price sensitive information (UPSI) to be discussed

Jupiter Life Line Hospitals (JLHL) reported a total income of Rs 411 Cr for Q1 FY27, with an EBITDA of Rs 79.3 Cr and a margin of 19.3%. The performance was impacted by the first full quarter of operations at the Dombivli hospital, which resulted in a planned EBITDA drag of Rs 9.5 Cr. Management maintains a target of reaching 2,500 beds by FY2027, supported by a balanced capital structure with approximately Rs 500 Cr in both debt and cash. The company reported an ARPOB of Rs 73,500 and an occupancy of 59.6% for the quarter.

• Total income for Q1 FY27 stood at Rs 411 Cr, representing approximately 27% of the TTM revenue of Rs 1,494 Cr.
• Dombivli hospital reported an EBITDA loss of Rs 9.5 Cr in its first full operational quarter, with fixed costs at Rs 6-7 Cr per month.
• Average Revenue Per Occupied Bed (ARPOB) reached Rs 73,500, driven by a 10% growth attributed to case mix and pricing.
• Overall occupancy stood at 59.6%, diluted by the addition of new beds at the Dombivli facility.
• Management reiterated a capacity expansion target to 2,500 beds by FY2027 from the current 1,061 beds.

Jupiter Life Line Hospitals (JLHL) has released the audio recording of its Q1 FY27 analyst call held on August 3, 2026. The company, which currently operates 1,061 beds, is focused on its strategy to reach 2,500 beds through greenfield expansions in Dombivli, Pune, and Mira Road. With a TTM revenue of ₹1,494 Cr and an OPM of 22.9%, the management discussion likely centered on the execution of these projects and ARPOB trends. The stock currently trades at a P/E of 10.8, which is notably lower than many hospital peers despite an 18-20% expected growth rate.

• Audio recording released for the Q1 FY27 conference call held on August 3, 2026
• Company is executing a plan to double bed capacity from 1,061 to 2,500 by FY2027
• TTM Revenue stands at ₹1,494 Cr with a healthy ROCE of 16.0%
• Operating Profit Margin (OPM) maintained at 22.9% as per TTM figures

Jupiter Life Line Hospitals Limited (JLHL) has updated its list of Key Managerial Personnel (KMP) authorized to determine the materiality of events or information under SEBI Regulation 30(5). Effective July 31, 2026, CFO Mr. Harshad Purani has been authorized in addition to MD & CEO Dr. Ankit Thakker. Ms. Suma Upparatti, Company Secretary, remains the authorized person for making disclosures to the stock exchanges. This is a standard administrative update to ensure regulatory compliance and does not impact the company's financial performance or its ongoing expansion plans.

• Board of Directors authorized CFO Harshad Purani for materiality determination on July 31, 2026
• MD & CEO Dr. Ankit Thakker remains an authorized personnel for determining materiality
• Company Secretary Suma Upparatti is the designated officer for making disclosures to Stock Exchanges
• The company maintains its operational focus on expanding from 1,061 beds to 2,500 beds by FY2027

Jupiter Life Line Hospitals (JLHL) reported a 16.2% YoY revenue growth to ₹392.6 Cr for Q1 FY27, supported by a 9.2% increase in ARPOB to ₹73,500. However, PAT declined 14.7% YoY to ₹37.5 Cr, primarily due to a ₹9.5 Cr EBITDA loss at the newly commissioned Dombivli facility and higher depreciation/finance costs. The company is aggressively pursuing a capacity expansion from 1,700 to 2,900 beds across Pune, Mira Road, and BKC. With ₹537.7 Cr in cash and investments, the company remains well-funded for its greenfield projects.

• Revenue from operations increased 16.2% YoY to ₹392.6 Cr for the quarter ended June 30, 2026.
• ARPOB (Average Revenue Per Occupied Bed) grew to ₹73,500 from ₹67,300 in the previous year.
• Dombivli hospital completed its first full quarter with an EBITDA loss of ₹9.5 Cr, in line with management guidance.
• Planned bed capacity expansion to 2,900 beds at an average cost of ~₹1.5 Cr per bed (excluding land).
• Consolidated EBITDA margin compressed to 19.3% from 22.2% YoY due to initial ramp-up costs and marketing expenses.

Jupiter Life Line Hospitals (JLHL) reported a 12.7% YoY increase in Q1 FY27 revenue to ₹328.5 cr, but net profit declined 14% YoY to ₹37.2 cr due to a sharp rise in operating expenses. The company announced the acquisition of Sulcus Private Limited for ₹3.78 cr from its promoters to set up an IV fluid manufacturing facility, marking a move into backward integration. This new venture will require an additional investment of ₹35-40 cr over the next 1-2 years. Additionally, the board appointed Harshad Purani as the new CFO, effective July 31, 2026.

• Revenue from operations grew 12.7% YoY to ₹328.49 cr in Q1 FY27.
• Net profit for the quarter stood at ₹37.19 cr, down from ₹43.29 cr in the same period last year.
• Acquired 100% of Sulcus Private Limited for ₹3.78 cr in a related-party transaction with promoters.
• Planned investment of ₹35-40 cr for an IV fluid manufacturing line near Ujjain, Madhya Pradesh.
• Total expenses increased to ₹286.50 cr in Q1 FY27 compared to ₹230.07 cr in Q1 FY26.

Jupiter Life Line Hospitals Limited (JLHL) has scheduled its earnings conference call for Q1 FY27 on Monday, August 3, 2026, at 10:00 AM IST. The call will be led by Managing Director and CEO Dr. Ankit Thakker to discuss the company's financial and operational performance. This follows a trailing twelve-month (TTM) revenue of ‡1,494 Cr and a PAT of ‡194 Cr. Investors will likely seek updates on the company's ambitious plan to expand bed capacity from 1,061 to 2,500 beds by FY2027.

• Earnings conference call scheduled for August 3, 2026, at 10:00 AM IST
• Management representation includes MD and CEO Dr. Ankit Thakker and the senior management team
• Discussion will cover operational and financial performance for the quarter ended June 30, 2026 (Q1 FY27)
• Company currently operates 1,061 beds with a target to reach 2,500 beds through greenfield projects
• TTM revenue stands at ‡1,494 Cr with an operating profit margin of 22.9%

Jupiter Life Line Hospitals (JLHL) shareholders approved all nine resolutions at the 24th AGM held on July 17, 2026. Key approvals include a sub-division (stock split) of equity shares and a material related party transaction with Jupiter Hospital Projects Private Limited. The related party transaction was passed with 100% of the 2.80 crore votes polled in favor (excluding promoters). Additionally, Dr. Ajay Thakker was re-designated as Chairman and Whole Time Director effective July 17, 2026.

• Approval of equity share sub-division (stock split) to enhance market liquidity.
• Material Related Party Transaction approved with 2,80,75,215 votes in favor (100% of valid votes polled for this item).
• Total of 32,977 shareholders were on record as of the July 10, 2026 cut-off date.
• Dr. Ajay Thakker appointed as Chairman & Whole Time Director with effect from July 17, 2026.
• Adoption of FY26 financial statements passed with 85.94% of total shares polled.

Jupiter Life Line Hospitals (JLHL) has finalized July 24, 2026, as the record date for its equity share sub-division. Each existing share with a face value of ₹10 will be split into 5 shares with a face value of ₹2 each. This corporate action was approved by shareholders at the Annual General Meeting held on July 17, 2026. The split is a procedural move to increase the number of outstanding shares and potentially improve liquidity for retail investors.

• Stock split ratio of 1:5, subdividing ₹10 face value shares into ₹2 face value shares
• Record date for determining eligibility fixed as Friday, July 24, 2026
• Shareholder approval obtained at the AGM on July 17, 2026
• Current market price of ₹1554.0 will be adjusted proportionally on the ex-split date

Jupiter Life Line Hospitals (JLHL) concluded its 24th AGM on July 17, 2026, where shareholders approved a sub-division (split) of equity shares. The meeting also ratified the appointment of Dr. Ajay Thakker as Chairman & Whole Time Director and approved a material Related Party Transaction (RPT) with Jupiter Hospital Projects Private Limited. These approvals come as the company maintains its TTM revenue of Rs 1,494 Cr and continues its strategy to expand bed capacity from 1,061 to 2,500. The formal adoption of FY26 financial statements confirms a TTM PAT of Rs 194 Cr.

• Shareholders approved the sub-division/split of equity shares to improve market liquidity (ratio not disclosed).
• Approval granted for a material Related Party Transaction with Jupiter Hospital Projects Private Limited.
• Dr. Ajay Thakker appointed as Chairman & Whole Time Director effective July 17, 2026.
• Formal adoption of FY26 Audited Financial Statements with TTM Revenue of Rs 1,494 Cr.
• Company reaffirmed its 'all-hub-no-spoke' strategy to reach 2,500 beds by FY2027.

Jupiter Life Line Hospitals Limited (JLHL) has submitted its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The company's Registrar and Share Transfer Agent, KFin Technologies Limited, confirmed that all securities of the company are held in dematerialized form as of June 30, 2026. No requests for rematerialization were received during the quarter. This filing is a routine administrative requirement to ensure the integrity of the company's shareholding records.

• Compliance certificate issued for the quarter ended June 30, 2026
• 100% of the company's holdings are confirmed to be in Demat form
• Zero rematerialization requests were received during the three-month period
• Confirmation provided by Registrar and Share Transfer Agent, KFin Technologies Limited

Jupiter Life Line Hospitals Limited (JLHL) has announced its 24th Annual General Meeting (AGM) for July 17, 2026. The company has dispatched letters to shareholders whose email addresses are not registered, providing web links to the FY 2025-26 Annual Report and AGM Notice. This is a standard regulatory procedure following the conclusion of the financial year. Investors should utilize the Annual Report to track the progress of the company's ambitious plan to expand bed capacity from 1,061 to 2,500 by FY2027.

• 24th Annual General Meeting scheduled for July 17, 2026, at 11:00 AM IST via Video Conferencing.
• Annual Report for the Financial Year 2025-26 and AGM Notice have been uploaded to the company website.
• Email registration status for dispatch purposes was determined as of June 19, 2026.
• Company is maintaining its focus on doubling bed capacity to 2,500 through greenfield facilities.

Jupiter Life Line Hospitals Limited (JLHL) has announced the closure of its trading window starting July 1, 2026, in compliance with SEBI Insider Trading regulations. The closure is ahead of the declaration of the Unaudited Financial Results for the quarter ending June 30, 2026. The restriction applies to all Designated Persons and their immediate relatives and will remain in effect until 48 hours after the results are made public. NSDL has been designated to enforce this by freezing PANs at the security level for ISIN INE682M01012.

• Trading window closure effective from Wednesday, July 1, 2026.
• Closure pertains to the Unaudited Financial Results for the quarter ending June 30, 2026.
• Restriction ends 48 hours after the financial results are declared to the Stock Exchanges.
• NSDL will restrict trading by freezing PANs for ISIN INE682M01012 as per SEBI circulars.
• Applies to all Designated Persons and their immediate relatives.